This agrees with the stronger reduction of CDX2 target genes, like Sis and Ces [40, 41], as well as with stronger upregulation of Cldn18, which has been negatively correlated with CDX2 expression and associated with poor survival in CRC patients [47] (Fig. 1b). The gene discussed is PDGFB; the disease is colorectal carcinoma.